In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate

European Journal of Pharmaceutical Sciences

Volumn 43, Issue 1-2, 2011, Pages 41-49

  Elsby, Robert ^a   Fox, Lisa ^b   Stresser, David ^b   Layton, Mark ^a   Butters, Caroline ^a   Sharma, Pradeep ^a   Smith, Veronica ^a   Surry, Dominic ^a  

^a ASTRAZENECA   (United Kingdom)

^b Discovery Labware   (United States)

Author keywords

Breast cancer resistance protein; Drug development; Drug drug interactions; Methotrexate; Rheumatoid arthritis; Transporters

Indexed keywords

ANTIRHEUMATIC AGENT; AZD9056; BREAST CANCER RESISTANCE PROTEIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ELIMINATION; DRUG INTERACTION; DRUG TRANSPORT; HUMAN; IC 50; IN VITRO STUDY; MEMBRANE VESICLE; OOCYTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; RISK ASSESSMENT; SULFASALAZINE; XENOPUS LAEVIS;

EID: 79955691418     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.03.006     Document Type: Article

References (34)

1. K.K. Adkison, S.S. Vaidya, D.Y. Lee, S. Hwee Koo, L. Li, A.A. Mehta, A.S. Gross, J.W. Polli, J.E. Humphreys, Y. Lou, and E.J.D. Lee Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration J. Pharm. Sci. 99 2010 1046 1062
2. American College of Rheumatology Recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum. 59 2008 762 784
3. C. Astbury, A.J. Taggart, L. Juby, L. Zebouni, and H.A. Bird Comparison of the single dose pharmacokinetics of sulfasalazine in rheumatoid arthritis and inflammatory bowel disease Ann. Rheum. Dis. 49 1990 587 590 (Pubitemid 20225426)
4. P. Breedveld, N. Zelcer, D. Pluim, Ö. Sönmezer, M.M. Tibben, J.H. Beijnen, A.H. Schinkel, O. van Tellingen, P. Borst, and J.H.M. Schellens Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions Cancer Res. 64 2004 5804 5811 (Pubitemid 39095580)
5. H.A. Capell, R. Madhok, D.R. Porter, R.A.L. Munro, I.B. McInnes, J.A. Hunter, M. Steven, A. Zoma, E. Morrison, M. Sambrook, F.W. Poon, R. Hampson, F. McDonald, A. Tierney, N. Henderson, and I. Ford Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study Ann. Rheum. Dis. 66 2007 235 241 (Pubitemid 46226060)
6. A.A.K. El-Sheikh, J.J.M.W. van den Heuvel, J.B. Koenderink, and F.G.M. Russel Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport J. Pharmacol. Exp. Ther. 320 2007 229 235 (Pubitemid 46025738)
7. European Medicines Agency, 2010. Guideline on the Investigation of Drug Interactions. Available from: < http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2010/05/WC500090112.pdf/ >.
8. M.G. Feely, A. Erickson, and J.R. O'Dell Therapeutic options for rheumatoid arthritis Expert Opin. Pharmacother. 10 2009 2095 2106
9. K.M. Giacomini, S.-M. Huang, D.J. Tweedie, L.Z. Benet, K.L.R. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K.M. Hillgren, K.A. Hoffmaster, T. Ishikawa, D. Keppler, R.B. Kim, C.A. Lee, M. Niemi, J.W. Polli, Y. Sugiyama, P.W. Swaan, J.A. Ware, S.H. Wright, S. Wah Yee, M.J. Zamek-Gliszczynski, and L. Zhang Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
10. C. Godfrey, K. Sweeney, K. Miller, R. Hamilton, and J. Kremer The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis Br. J. Clin. Pharmacol. 46 1998 369 376
11. C.J. Haagsma, P.L. van Riel, D.J. de Rooij, T.B. Vree, F.J. Russel, M.A. van't Hof, and L.B. van de Putte Combination of methotrexate and sulfasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulfasalazine therapy Br. J. Rheumatol. 33 1994 1049 1055
12. C.J. Haagsma, F.G.M. Russel, T.B. Vree, P.L.C.M. van Riel, and L.B.A. van de Putte Combination of methotrexate and sulfasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response Br. J. Clin. Pharmacol. 42 1996 195 200 (Pubitemid 26255065)
13. R.A. Hamilton, and J.M. Kremer Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis Br. J. Rheum. 36 1997 86 90
14. M. Jani, P. Szabo, E. Kis, E. Molnar, H. Glavinas, and P. Krajcsi Kinetic characterisation of sulfasalazine transport by human ATP-binding cassette G2 Biol. Pharm. Bull. 32 2009 497 499
15. J.E. Karlsson, C. Heddle, A. Rozkov, J. Rotticci-Mulder, O. Tuvesson, C. Hilgendorf, and T.B. Andersson High activity P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-Epstein-Barr virus nuclear antigen cells Drug Metab. Dispos. 38 2010 705 714
16. A. Maeda, S. Tsuruoka, Y. Kanai, H. Endou, K. Saito, E. Miyamoto, and A. Fujimura Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells Eur. J. Pharmacol. 596 2008 166 172
17. Y. Nozaki, H. Kusuhara, T. Kondo, M. Iwaki, Y. Shiroyanagi, H. Nakayama, S. Horita, H. Nakazawa, T. Okano, and Y. Sugiyama Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices J. Pharmacol. Exp. Ther. 322 2007 162 170
18. Orion Pharma (UK) Ltd., 2008. Methotrexate Summary of Product Characteristics. < www.medicines.org.uk/EMC/ > (accessed 29.04.10).
19. Pharmacia & Upjohn Company, 2001. Azulfidine EN-tabs® (Sulfasalazine Delayed Release Tablets, USP) Prescribing Information Label 007073/S-115 (2001-Aug-17). < www.pharmapendium.com/ > (accessed 20.04.10).
20. T. Pincus, Y. Yazici, T. Sokka, D. Aletaha, and J.S. Smolen Methotrexate as the anchor drug for the treatment of early rheumatoid arthritis Clin. Exp. Rheumatol. 21 2003 S-179 S-185
21. P. Seideman, O. Beck, S. Eksborg, and M. Wennberg The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis Br. J. Clin. Pharmacol. 35 1993 409 412 (Pubitemid 23103382)
22. J. Swierkot, and J. Szechinski Methotrexate in rheumatoid arthritis Pharmacol. Rep. 58 2006 473 492 (Pubitemid 44383273)
23. M. Takeda, S. Khamdang, S. Narikawa, H. Kimura, M. Hosoyamada, S.H. Cha, T. Sekine, and H. Endou Characterization of methotrexate transport and its drug interactions with human organic anion transporters J. Pharmacol. Exp. Ther. 302 2002 666 671 (Pubitemid 34787234)
24. B.L. Urquhart, J.A. Ware, R.G. Tirona, R.H. Ho, B.F. Leake, U.I. Schwarz, H. Zaher, J. Palandra, J.C. Gregor, G.K. Dresser, and R.B. Kim Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe Pharmacogenet. Genomics 18 2008 439 448 (Pubitemid 351535945)
25. US Food and Drug Administration, 1999. Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA). Available from: < http://www.fda.gov/cder/guidance.com/ >.
26. US Food and Drug Administration, 2006. Draft Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling. Available from: < http://www.fda.gov/cder/guidance.com/ >.
27. Y. Uwai, R. Tangiguchi, H. Motohashi, H. Saito, M. Okuda, and K.-I. Inui Methotrexate-loxoprofen interactions: involvement of human organic anion transporters hOAT1 and hOAT3 Drug Metab. Pharmacokinet. 19 2004 369 374
28. A.L. VanWert, and D.H. Sweet Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates Pharm. Res. 25 2008 453 462 (Pubitemid 351257979)
29. J.W. van der Heijden, R. Oerlemans, P.P. Tak, Y.G. Assaraf, M.C. Kraan, G.L. Scheffer, C.J. van der Laken, W.F. Lems, R.J. Scheper, B.A.C. Dijkmans, and G. Jansen Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide Arthritis Rheum. 60 2009 669 677
30. E.N. van Roon, P.M.L.A. van den Bemt, T.L.T.A. Jansen, N.M. Houtman, M.A.F.J. van de Laar, and J.R.B.J. Brouwers An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists Clin. Ther. 31 2009 1737 1746
31. M.L. Vlaming, K. Mohrmann, E. Wagenaar, D.R. de Waart, R.P. Elferink, J.S. Lagas, O. van Tellingen, L.D. Vainchtein, H. Rosing, J.H. Beijnen, J.H. Schellens, and A.H. Schinkel Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice J. Pharmacol. Exp. Ther. 318 2006 319 327
32. M.E. Weinblatt Methotrexate in rheumatoid arthritis: toxicity issues Br. J. Rheumatol. 35 1996 403 406
33. L. Zhang, J.M. Strong, W. Qiu, L.J. Lesko, and S.-M. Huang Scientific perspectives on drug transporters and their role in drug interactions Mol. Pharm. 3 2006 62 69 (Pubitemid 43331752)
34. L. Zhang, Y.D. Zhang, J.M. Strong, K.S. Reynolds, and S.-M. Huang A regulatory viewpoint on transporter-based drug interactions Xenobiotica 38 2008 709 724